Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 7/20 | 0.35 |
| ▸ | BCR | P11274 | 7/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27912561 | 0.85 | PDE10A (0.44) | HCRTR2ABL1BCRJAK3 | |
| SCHEMBL16209160 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2HCRTR2ABL1BCRMAPT | |
| SCHEMBL4304308 | 0.84 | ABL1 (0.52) | SMN1; SMN2HCRTR2ABL1BCROPRK1 | |
| SCHEMBL1018117 | 0.80 | CNR2 (0.39) | SMN1; SMN2HCRTR2ABL1BCRNEK2 | |
| SCHEMBL4304300 | 0.79 | F10 (0.39) | HCRTR2ABL1BCRMAPT | |
| SCHEMBL4307471 | 0.75 | CKS1B (0.41) | — | |
| SCHEMBL14812129 | 0.75 | MAP4K4 (0.37) | OPRK1OPRM1OPRD1OGFRL1JAK3 | |
| SCHEMBL3650736 | 0.74 | TRPV1 (0.46) | OPRD1JAK3 | |
| SCHEMBL4304311 | 0.74 | JAK3 (0.36) | OPRK1POLBOPRM1OPRD1OGFRL1 | |
| SCHEMBL1018116 | 0.73 | ABL1 (0.39) | SMN1; SMN2HCRTR2ABL1BCRNEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | SMN1; SMN2 4561/4885HCRTR2 4736/4885ABL1 16/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | SMN1; SMN2 4561/4885HCRTR2 4736/4885ABL1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.